

### Amendments to the Claims

A detailed listing of all claims that are, or were, in the present application, irrespective of whether the claim(s) remains under examination in the application are presented below. The claims are presented in ascending order and each includes one status identifier. Those claims not cancelled or withdrawn but amended by the current amendment utilize the following notations for amendment: 1) deleted text is shown by strikethrough for six or more characters and double brackets for five or less characters; and 2) added text is shown by underlining.

### **CLAIMS**

1. (Currently Amended) A method of promoting viability of a transplant cell population comprising contacting the transplant cell population *in vitro* with an effective amount of a compound selected from the group consisting of ursodeoxycholic acid, a salt thereof, an analog thereof, and a combination thereof, wherein cells of the prepared transplant cell population are human dopamine neurons or precursors thereof.
2. (Previously presented) The method of claim 1 wherein cells of the transplant cell population are differentiated dopamine neurons.
3. (Previously presented) The method of claim 1 wherein cells of the transplant cell population are precursor cells of dopamine neurons selected from the group consisting of pluripotent stem cell, embryonic stem cells, adult stem cells and combinations thereof.
4. – 6. (Canceled).

7. (Previously presented) The method of claim 1 wherein contacting the transplant cell population with the compound comprises contacting the transplant cell population with the compound *in vitro* prior to transplanting the transplant cell population in a subject.

8. (Previously presented) The method of claim 7 wherein the subject is a human.

9. – 14. (Canceled)

15. (Original) The method of claim 1 wherein contacting the transplant cell population with the compound comprises contacting the transplant cell population in combination with a pharmaceutically acceptable carrier.

16. (Original) The method of claim 1 wherein the cells of the transplant cell population comprise autologous cells, heterologous cells, or xenologous cells.

17. (Original) The method of claim 1 wherein the cells of the transplant cell population comprises at least a portion of autologous tissue, heterologous tissue, or xenologous tissue.

18. – 65. (Canceled)

66. (Previously presented) The method of claim 1 wherein the ursodeoxycholic acid analog includes a conjugated derivative.

67. (Previously presented) The method of claim 66 wherein the conjugated derivative is tauroursodeoxycholic acid.

68. (Previously presented) The method of claim 1 wherein the dopamine neurons are human embryonic dopamine neurons.

69. – 77. (Canceled)

78. (Previously presented) The method of claim 1 wherein the cells of the transplant cell population are embryonic ventral mesencephalic cells.

79. – 80. (Canceled)